DYAI Key Statistics, Chart & Performance
The current stock price of DYAI is 0.912 USD. In the past month the price decreased by -8.78%. In the past year, price decreased by -37.96%.
DYAI Technical Analysis
DYAI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DYAI. DYAI may be in some trouble as it scores bad on both profitability and health.
DYAI Financial Highlights
Over the last trailing twelve months DYAI reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -4.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.95% | ||
| ROE | -281.84% | ||
| Debt/Equity | 1.92 |
DYAI Forecast & Estimates
7 analysts have analysed DYAI and the average price target is 7.14 USD. This implies a price increase of 682.89% is expected in the next year compared to the current price of 0.912.
For the next year, analysts expect an EPS growth of -14.75% and a revenue growth -10.33% for DYAI
DYAI Ownership
About DYAI
Company Profile
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 6 full-time employees. The company went IPO on 2004-11-05. The firm's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The firm has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Company Info
DYADIC INTERNATIONAL INC
1044 North U.S. Highway One, Suite 201
Jupiter FLORIDA 33477 US
CEO: Mark A. Emalfarb
Employees: 6
Phone: 15617438333
DYADIC INTERNATIONAL INC / DYAI FAQ
What does DYADIC INTERNATIONAL INC do?
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 6 full-time employees. The company went IPO on 2004-11-05. The firm's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The firm has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Can you provide the latest stock price for DYADIC INTERNATIONAL INC?
The current stock price of DYAI is 0.912 USD. The price increased by 2.68% in the last trading session.
Does DYAI stock pay dividends?
DYAI does not pay a dividend.
What is the ChartMill rating of DYADIC INTERNATIONAL INC stock?
DYAI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for DYADIC INTERNATIONAL INC?
DYADIC INTERNATIONAL INC (DYAI) will report earnings on 2026-03-24, after the market close.
What is the outstanding short interest for DYADIC INTERNATIONAL INC?
The outstanding short interest for DYADIC INTERNATIONAL INC (DYAI) is 0.74% of its float.